⌕
Vertex Pharmaceuticals · VRTX · Nasdaq
Tenet 55 · Mixed
Compare
$534.20−0.67%At closeTenet 55 · Mixed
$534.20−3.59 (−0.67%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
$534.200.00 (0.00%)
After hours: Nov 17, 2026, 5:52 PM ET

Vertex Pharmaceuticals (VRTX) Stock

Vertex Pharmaceuticals (VRTX) closed at $534.20 on Nov 17, 2026; its Tenet Score is 55 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

11 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$534.20
Nov 17, 2026
Market cap
$136.4B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
34.5×
TTM through Sep 30, 2026 · as of close, Nov 16, 2026
52-week range
412.27 – 568.67
low → high · as of close, Nov 16, 2026
Tenet Score
55/100
Mixed · 340 Healthcare peers

Industry: Drugs

Vertex Pharmaceuticals, Inc. scores 55/100. Mixed. Strongest on quality, value is the soft spot, trading at 35× earnings versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
55/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
33
Quality
72
Health
50
Growth
65

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueDQualityBHealthCGrowthCMomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
6.5×
Sep 30, 2026 balance sheet
P/S
10.5×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
21%
TTM through Sep 30, 2026
Operating margin
34.8%
fiscal 2025, before interest and tax
Net margin
30.7%
TTM through Sep 30, 2026
Current ratio
2.34
Sep 30, 2026 balance sheet
Net debt / EBITDA
−0.4×
TTM through Sep 30, 2026
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specif…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 424 US ETFs · top wrappers by weightSee all ETFs holding VRTX →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

CompanyTenet ScoreMarket cap
Novartis AGNVS55$305.7B
AMGEN Inc.AMGN47$250.1B
Gilead Sciences, Inc.GILD38$207.9B
Novo NordiskNVO62$185.7B
Pfizer Inc.PFE50$164.5B
Bristol-Myers Squibb Co.BMY51$128.6B
GSK PlcGSK51$108.8B
Regeneron Pharmaceuticals, Inc.REGN64$98.5B
Moderna IncMRNA33$87.1B
Takeda Pharmaceutical CoTAK32$74.4B

Compare Vertex Pharmaceuticals with

What sector and industry is Vertex Pharmaceuticals in?

Vertex Pharmaceuticals is in the Healthcare sector and the Drugs industry.

What is Vertex Pharmaceuticals' Tenet Score?

Vertex Pharmaceuticals' Tenet Score is 55 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.